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Abstract.  Proteolipid protein (PLP) is the most abun- 
dant transmembrane  protein in myelin of the central 
nervous system. Conflicting models of PLP topology 
have been generated by computer predictions based on 
its primary sequence and experiments with purified 
myelin.  We have examined the initial  events in myelin 
synthesis,  including  the insertion  and orientation of 
PLP in the plasma membrane,  in rat oligodendrocytes 
which express PLP and the other myelin-specific pro- 
teins when cultured without neurons (Dubois-Dalcq, 
M.,  T.  Behar,  L.  Hudson, and R. A.  Lazzarini.  1986. 
J.  Cell Biol.  102:384-392).  These cells,  identified by 
the presence of surface galactocerebroside, the major 
myelin glycolipid, were stained with six anti-peptide 
antibodies directed against hydrophilic or short hydro- 
phobic sequences of PLP.  Five of these anti-peptide 
antibodies specifically stained living oligodendrocytes. 
Staining  was only seen •10  d after PLP was first de- 
tected in the cytoplasm of fixed and permeabilized 
cells,  suggesting that PLP is slowly transported  from 
the RER to the cell surface.  The presence of PLP do- 
mains on the extracellular surface was also confirmed 
by cleavage of such domains with proteases and by 
antibody-dependent complement-mediated lysis of liv- 
ing oligodendrocytes. Our results indicate that PLP 
has only two transmembrane domains and that the 
great majority of the protein,  including  its amino and 
carboxy termini,  is located on the extracellular face of 
the oligodendrocyte plasma membrane.  This disposi- 
tion of the PLP molecule suggests that homophilic  in- 
teractions between PLP molecules of apposed extracei- 
lular faces may mediate compaction of adjacent 
bilayers in the myelin sheath. 
T 
HE myelin  sheath  in the central  nervous system is a 
specialized  extension  of the oligodendrocyte plasma 
membrane that enwraps axons, thereby permitting  fast 
saltatory  conduction of nerve impulses  (for review see 51). 
An oligodendrocyte extends as many as 20 processes, each 
of which contacts and repeatedly envelops a stretch of axon 
with subsequent condensation of the encircled membranes to 
form a compact sheath (51). The sheath has an atypical abun- 
dance of lipid,  with a lipid-to-protein  ratio of 80:20 (wt/wt) 
in myelin vs. 55:45 in the oligodendrocyte plasma membrane 
and a limited repertoire of proteins  (28, 42). Moreover,  the 
two proteins that comprise the bulk of myelin, myelin basic 
protein (MBP)' and proteolipid protein (PLP), each contain 
covalently attached  lipid on at least a fraction  of the mole- 
cules (5, 60, 61, 64, 70). MBP is a peripheral  membrane pro- 
tein  localized  on the cytoplasmic  face of the myelin mem- 
brane  that  functions  in  the  compaction  of the  sheath,  as 
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suggested by the absence of a compact major dense line in 
shiverer mice mutants  unable to synthesize  MBP (35, 49, 
53).  PLP is  an  extremely hydrophobic  protein  with  75% 
a-helical content (7) that spans the myelin membrane (10, 25, 
27, 28, 48, 62). The primary sequence of PLP is strikingly 
conserved among  species:  human,  mouse, and rat PLP are 
identical  and differ  from bovine PLP at only three amino 
acids (11, 14, 21, 22, 34, 38, 39, 50). Although the function 
of PLP in the myelin sheath is not clear, a structural  role is 
likely  simply  because PLP constitutes  half of the myelin 
protein. 
The initial events in myelin assembly, including the traffick- 
ing of myelin-specific proteins and lipids to the oligodendro- 
cyte plasma membrane and the subsequent segregation  of 
myelin components within the plasma membrane which must 
occur before sheath  formation,  are  largely  unknown  (for 
reviews see Benjamins  [3] and Morell and Toews [36]).  As 
suggested for other systems of membrane assembly (for re- 
view see Pfeffer and Rothman  [47]),  various pathways may 
be involved in targeting myelin constituents to sites of assem- 
bly.  For  example,  myelin  constituents  synthesized  in  the 
RER, such as PLP (8) and myelin-associated  glycoprotein 
(MAG), may be packaged as precursor vesicles for constitu- 
tive (bulk flow) or regulated  transport  (as described in 47) 
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suggested previously by the subcellular fractionation studies 
of Pereyra et al. (45, 46) and the ability of monensin to dis- 
rupt PLP transport to myelin (63). Other myelin components 
could be synthesized at or very close to the myelin membrane 
for direct insertion. MBP is a candidate for this pathway be- 
cause the message for MBP, which is translated on free ribo- 
somes (8), is present in oligodendrocyte processes (72) and 
in subcellular fractions comprising compact myelin (8, 33). 
Thus, nascent MBP might be targeted to sites of myelin as- 
sembly in the immediate vicinity of the translating ribosome 
shortly after the covalent addition of phosphatidylinositol 
bisphosphate (70).  Most of the myelin-specific lipids,  in- 
cluding the myelin marker galactocerebroside (GC), are syn- 
thesized on intracytoplasmic membranes and may be trans- 
ported in vesicles or individually by some of the putative 
carrier proteins in brain shown to bind to sulfatides, cerebro- 
sides, or phospholipids (for review see Morell and Toews 
[36]). 
The simplicity of the myelin membrane and the availability 
of cultured oligodendrocytes affords a unique system to ap- 
proach questions of membrane assembly. We have previ- 
ously observed that rat oligodendrocytes cultured without 
neurons express myelin-specific constituents and that the ini- 
tial stages of myelin assembly can be studied in such cells 
(16). To examine myelin architecture and assembly at a mo- 
lecular level, we have analyzed the structure of the major my- 
elin protein, PLP, in the oligodendrocyte plasma membrane. 
PLP was the focus of these studies because the topology of 
this abundant protein is likely to dominate the structure of 
myelin and possibly organize the other components of my- 
elin. In addition, knowledge of which PLP epitopes reside 
on the oligodendrocyte surface may be important in unravel- 
ing  the  pathology  of  demyelinating  diseases,  including 
models  such  as  experimental  allergic  encephalomyelitis 
which can be induced by purified PLP (57, 68).  The advan- 
tages of the oligodendrocyte culture system to probe PLP 
structure include the ability to readily stain by immunofluo- 
rescence for myelin proteins and lipids, unlike the situation 
for compact myelin in which PLP and other proteins are rela- 
tively inaccessible unless the myelin is fixed or disrupted by 
procedures that can induce artifacts. Cultured oligodendro- 
cytes also afford the opportunity to observe PLP in its native 
conformation, unlike the case  for PLP reconstituted into 
artificial membranes (30).  Our approach has been to probe 
cultured oligodendrocytes with a panel of antibodies to pep- 
tides located mostly in hydrophilic regions of the molecule. 
The presence of PLP epitopes on the extracellular surface 
was assayed by three criteria: immunofluorescent labeling of 
living, nonpermeabilized oligodendrocytes, cleavage  of ex- 
tracellular epitopes with protease, and lysis of oligodendro- 
cytes in the presence of  the appropriate antibody and comple- 
ment. Contrary to computer predictions based on the primary 
sequence and other models of PLP topology (27, 30, 62), our 
results suggest that PLP has only two transmembrane do- 
mains, with the great majority of the protein located on the 
extracellular face of the oligodendrocyte  membrane. PLP ap- 
pears to be transported from the cell body to the processes 
via vesicles that eventually fuse with the plasma membrane 
after a long delay,  suggesting that PLP delivery is a regu- 
lated, signal-mediated process. 
Materials and Methods 
Preparation of  AJfinity-purified Antibodies 
The preparation of anti-PLP I antibody has been described earlier (16). Pep- 
tides were constructed by the Merrifield solid-phase technique with a Beck- 
man 990 (Beckman Instruments, Inc., Palo Alto, CA) or an Applied Bio- 
systems (Foster City, CA) automated peptide synthesizer. After synthesis, 
peptides were desalted on a Sephadex G-10 column, then analyzed, and, if 
necessary, purified by high pressure liquid chroma~graphy (Waters  As- 
sociates, Milford, MA). Synthetic peptides were coupled to the carrier key- 
hole limpet hemocyanin (Calbiochem-Behring Corp., La Jolla, CA) in 0.1% 
glutaraldebyde; 0.5 mg of each coupled peptide in Freund's incomplete adju- 
vant was distributed by subcutaneous injection to 10-15 sites per rabbit for 
each boost. Freund's complete adjuvant was used for the initial immuni- 
zation. 
Antiserum was purified first by passage through a protein A-Sepharose 
(Pharmacia  Fine  Chemicals,  Piscataway,  N J)  column  equilibrated  with 
PBS.  The  immunoglobulin  fraction  containing predominantly IgG  was 
eluted in 10% dioxane (J. T. Baker Chemical Co., Pillipsburg, NJ), 90% 
citrate phosphale buffer,  pH 2.4 (90 mM citric acid, 20 mM Na2HPO4), 
and dialyzed in PBS. The antibody was next applied to an affinity column 
prepared by coupling 10-20 mg peptide/ml of Affigel 10 as described by 
the manufacturer (Bio-Rad Laboratories, Rockville Centre, NY); coupling 
of the hydrophobic peptide PLP V I was carried out with the addition of  0.1% 
SDS to the coupling buffer (0.1 M  NaHCO3,  pH  8).  After an extensive 
PBS wash, columns were also washed in citrate phosphate buffer, pH 6 (37 
mM citric acid, 93 mM Na2HPO4),  before the anti-peptide antibody was 
eluted in 10% dioxane, 90% citrate phosphate buffer, pH 2.4. Purified anti- 
bodies were dialyzed against PBS and concentrated to 1 mg protein/ml with 
a Centricon 30 microconcentralor (Amicon Corp., Danvers, MA). PLP VI 
antisera was additionally purified by absorption to a monolayer of type l 
astrocytes. 
Purified antibodies were titered by a dot immunobinding assay as previ- 
ously detailed (16) and were tested for reactivity to PLP on immunoblots 
of SDS-polyacrylamide  gels  (12.5%  acrylamide;  30:1 acrylamide/bis) 
transblotted in 0.1% SDS, 25 mM Tris,  192 mM glycine, 20% methanol. 
An  alkaline  phosphatase-conjugated anti-rabbit  IgG  (Promega  Biotee, 
Madison, WI) was used to detect PLP-specific bands in samples of guinea 
pig or human myelin. Some preparations were also tested by ELISA (1), 
using chloroform-methanol  extract of human myelin (gift of R. Quarles, Na- 
tional Institute of Neurological Diseases and Stroke, National Institutes of 
Health, Bethesda, MD) or purified aqueous bovine PLP (gift of N. Potter, 
Department of Neurobiology, Harvard Medical School, Cambridge, MA) 
as antigen and detection with peroxidase-conjugated goat anti-rabbit IgG 
followed by 2,2'-Azinobis(3-ethylbenzthiazolinesulfonic  acid) (Sigma Chemi- 
cal Co., St.  Louis, MO). 
lmmunostaining of Cultured Oligodendrocytes 
Primary brain cultures devoid of neurons and cultures enriched for oligo- 
dendrocytes were prepared from newborn Sprague-Dawley rats as previ- 
ously described (16, 72), except that cerebral hemispheres were soaked in 
LI5 medium (Gibco Laboratories, Grand Island, NY) instead of MEM with 
25 mM Hepes. Most experiments were carried out with enriched oligoden- 
drocyte cultures. The ages mentioned in this paper are not the "in vitro" age 
but the postnatal rat age; for example, ifa l-d-old rat was killed and the brain 
dissociated and cultured for 17 d, the rat postnatal age would be 18 d. 
Immunostaining of living cells was carried out at 23°C in PBS or MEM- 
Hepes buffer as follows: buffer rinse, 0.5-1 min; anti-peptide primary anti- 
body,  20-30  min;  buffer rinse,  0.5-1  min;  fluorescein conjugated-goat 
anti-rabbit IgG antibody (Cooper Biomedical, Inc., Malvern, PA or ICN 
Biomedicals, Lisle, IL); buffer rinse, 1-2 min; 2% formaldehyde, 5-10 min; 
coverslip under Tris-glycerol. 
Double staining for surface PLP and GC was performed in two ways: 
(procedure 1) simultaneous live staining with anti-peptide and anti-GC an- 
tibodies; and (procedure 2) sequential staining. Procedure 1 was carried out 
as described above for anti-peptide antiserum alone, except that the primary 
mixture contained anti-GC (52) in addition to the anti-peptide antibody and 
the secondary mixture contained rhodamine-conjagated goat anti-mouse IgG 
in addition to the anti-rabbit secondary. For procedure 2, living ceils were 
stained with anti-peptide antiserum alone as described above.  Next, after 
formaldehyde fixation, the PLP-stained cells were treated with: buffer,  3 h; 
anti-GC in buffer with 10% goat serum and 10% rabbit serum, 1 h; buffer, 
30 min; 2% formaldehyde, 20 min; buffer, 20 h; biotinylated goat anti-mouse 
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biotin, 30 min; buffer, 10 min; rhodamine-conjugated streptavidin (Molecu- 
lar Probes Inc., Eugene, OR) with 1% BSA, 30 min; buffer,  10 min; 2% 
formaldehyde, 5 min; and coverslipped as above. 
Living cells incubated with either mouse anti-GC or rabbit anti-peptide 
antibodies followed by the inappropriate conjugate did not show any stain. 
The latter control was extremely critical, as a  number of commercially 
available lots of fluorescein-conjugated goat anti-rabbit IgG antibody were 
found to react with the mouse monoclonal anti-GC antibody. 
In experiments aimed at detecting intracytoplasmic PLP, cells were fixed 
with 4 % paraformaldehyde for 20 min and permeabilized by a 5-min 0.05 % 
Triton X-100 treatment before staining. 
Peptide competition experiments were carried out by including each pep- 
tide (final  concentration of 1 mg/ml  MEM with 25  mM Hepes) in the 
20-min incubation with the corresponding anti-peptide antibody (14 og/ml) 
and anti-GC antibody. To control for nonspecific competition, each anti- 
peptide antibody was also tested for its ability to stain oligodendrocytes in 
the presence of an unrelated PLP peptide; for example, PLP I peptide was 
added to  the  anti-PLP IV  antibody and  did  not abrogate  PLP  IV  im- 
munofluorescence. When cells were double labeled for PLP and MAG, cul- 
tures were fixed with 1% formaldehyde and 0.05%  saponin for 20 min and 
then labeled with mouse monoclonal antibody to MAG (kindly provided by 
R. Quarles; reference 15) and rabbit anti-PLP peptide antibody followed 
by goat anti-mouse lgG rhodamine and goat anti-rabbit fluorescein con- 
jugates. 
Protease Treatment of Cultured Oligodendrocytes 
Primary rat brain cultures grown in 75-cm  2 Falcon flasks were prepared in 
two different manners for the protease experiments: (a)  cells were first 
scraped with a  rubber policeman and then washed and put in suspension 
containing 0.05%  trypsin and 0.02%  EDTA  in  Hanks' Ca- and Mg-free 
medium for 25 min at 37°C; or (b) monolayers were rinsed and directly in- 
cubated with 0.05%  trypsin and 0.02% EDTA in the same medium for 25 
min at 37°C. In either case, serum-containing medium was added and cells 
in suspension were washed before incubation with antibodies. The first pro- 
cedure resulted in more efficient proteolytic cleavage.  Living cells in sus- 
pension were stained with anti-GC and anti-peptide antibodies as described 
above. The total number of GC-positive cells as well as the total  number 
of GC-positive cells  that  were  also  stained  with  PLP  antibodies  were 
counted. In some experiments chymotrypsin (0.05 % in Hanks' balanced salt 
solution with 0.02%  EDTA;  Worthington Biochemical Corp.,  Freehold, 
NH) was substituted for trypsin. To test whether protease treatment exposed 
internal protein to antibody, living cells in suspension treated as described 
above were stained with rabbit anti-peptide antibody directed against actin 
(Miles-Yeda,  Rehovot, Israel) or a myelin basic protein sequence encoded 
by exon 6 of the MBP gene 03). 
Complemen t-dependen t Cytotoxicity Assays 
Cultures  enriched for oligodendrocytes were harvested by  scraping and 
counted. 6  ×  l04 cells were incubated with anti-peptide or anti-GC anti- 
body and rabbit complement (Cooper Biomedical, Inc.) for 15 rain at 37°C. 
Cells  were washed and  resuspended in  MEM  with 25  mM  Hepes and 
stained with 0.4%  trypan blue in PBS.  Since living cells exclude trypan 
blue, the number of stained dead cells was counted and the ratio to total cells 
calculated. 
To confirm the ability of protease to cleave extracellular PLP domains 
(as detailed above) and leave only residual amounts of PLP epitopes on the 
cell surface, parallel experiments were carried out on cells treated with tryp- 
sin before addition of antibody and complement. Cells were incubated with 
0.05%  trypsin at 37°C for 25 rain and washed thoroughly before continuing 
with antibody and complement incubations. 
All preparations for immunofluorescence were examined on a  micro- 
scope (photoscope II1; Carl  Zeiss, Inc.,  Thorwood,  NY)  equipped with 
epifluorescence and appropriate filters for rhodamine and fluorescein as 
well as a 63-oil objective. 
Results 
Most Anti-peptide Antibodies Stain Living 
Oligodendrocytes in Culture 
A hydropathy plot of PLP (Fig.  l) revealed four extremely 
hydrophobic sections of sufficient length to serve as trans- 
membrane  domains  (A-D) alternating  with  hydrophilic 
stretches of amino acids. To probe the orientation of PLP in 
the oligodendrocyte plasma membrane,  six peptides were 
chemically synthesized (Fig. 2; peptides were numbered by 
the order in which they were synthesized). Most of these 
peptides correspond to hydrophilic segments of PLP with the 
exception of  peptide VI, which is composed of a hydrophobic 
stretch from domain C.  Antibodies to each peptide were 
raised in rabbits and affinity purified on peptide columns. 
Each anti-peptide antibody reacted with PLP on immuno- 
blots, as shown for PLP I in an earlier publication (50); how- 
ever,  while anti-PLP I  reacted strongly, antibodies to the 
other peptides reacted only weakly. When assayed by ELISA, 
both anti-PLP I and anti-PLP V exhibited substantial im- 
munoreactivity to purified aqueous PLP and to chloroform- 
methanol extract of isolated myelin, but anti-PLP II, IV, 
and VI did not. Remarkably, anti-PLP III bound extremely 
weakly to untreated antigen, but strongly to antigen treated 
after adsorption by weak trypsin or chymotrypsin digestion 
or by fixation with glutaraldehyde. All the anti-peptide anti- 
bodies stained the cytoplasm of cultured oligodendrocytes 
strongly. While not definitive, these results suggest that the 
antibody-binding activity of PLP depends on the milieu in 
which the molecule presents itself and that PLP, when re- 
moved from biological membrane, may fold in ways which 
severely limit the availability of particular epitopes. 
Five of the anti-peptide antibodies (anti-PLP I, III, IV, V, 
and VI) labeled the surface of rat brain oligodendrocytes in 
culture at a time corresponding to the postnatal rat age of 
20-37  d  (Figs.  3  and 4).  The oligodendrocytes could be 
identified in phase contrast by their size and the characteris- 
tic branching pattern of their processes; their identity was 
verified by double staining cultures with antibody against GC 
in addition to the anti-peptide antibodies. Each anti-peptide 
antibody produced a  patchy pattern of surface label over 
oligodendrocyte cell bodies and processes  (Fig.  3,  a  and 
c-e), visible in both singly and doubly stained preparations. 
A  different pattern,  seen  in  oligodendrocyte cell  bodies 
stained after fixation and permeabilization, included focal 
intracytoplasmic and perinuclear fluorescence suggestive of 
an association with the Golgi and ER membrane systems 
(Fig. 3 b). 
Immunostaining with each anti-peptide antibody was com- 
pletely abolished in the presence of excess homologous pep- 
tide but  was  unaffected by a  nonhomologous peptide  (as 
shown in Fig. 4 for PLP IV), demonstrating the specificity 
of the surface label. 
Only the anti-PLP II antibody was unable to immunostain 
intact  oligodendrocytes,  although  it  readily  reacted  with 
oligodendrocytes that were first fixed and permeabilized with 
Triton X-100 (Fig. 5). Unlike the focal cytoplasmic stain of 
all other PLP antibodies, the PLP II antibody produced a 
diffuse pattern of cytoplasmic stain. Presumably PLP II was 
cross reacting with other rat intracellular proteins and these 
interactions were masking the patchy pattern of PLP stain- 
ing; PLP II antibody, as well as another peptide antibody 
directed against only the first eight amino acids of the PLP 
II peptide0 did react with other rat brain proteins in addition 
to PLP on immunoblots. 
A critical factor in the detection of PLP on the extracellu- 
lar face of the oligodendrocyte  plasma membrane was the age 
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Figure 1. Hydropathy plot of PLP. 
The  consensus  hydrophobicity 
scale of Eisenberg (20) was used. 
The  four  hydrophobic  domains 
are  indicated  as A-D;  the posi- 
tions  of  the  synthetic  peptides 
I-VI are  shown below  their  re- 
spective hydrophobic/hydrophilic 
segment• 
of the oligodendrocyte culture.  In preliminary experiments 
to determine the time course of PLP expression in cultures 
established from 1-2-d-old rats, we found that anti-PLP I an- 
tibody could label intact oligodendrocytes corresponding to 
a  minimal  rat postnatal age of 20 d  (18-19 d  of culture)• 
Shorter periods of culture failed to yield reproducible sur- 
face  staining  of PLP,  although  PLP  was  clearly  present 
throughout  the  cell  body  and  processes  of permeabilized 
oligodendrocytes as early as 14 d. Similar results were ob- 
tained with the other anti-peptide antibodies, so subsequent 
experiments were done with cultures >20 d old. 
The ability of anti-peptide I antibody to label the surface 
of  oligodendrocytes  (Fig.  3  a)  contradicts  the  work  of 
Trifilieff et  al.  (66),  who  constructed  a  synthetic  peptide 
(117-129)  that overlaps with our peptide I  (109-128).  The 
failure of their anti-peptide antibody to stain intact oligoden- 
drocytes is most likely attributable to the use of 18-19-d-old 
cultures that were not yet expressing PLP on the surface of 
the plasma membrane. As discussed above and in our previ- 
ous work (16), a time course of PLP expression in oligoden- 
drocytes cultured from newborn rat brain reveals that PLP 
is first detected in the cell body at 7-9 d (rat postnatal age), 
is spread throughout the processes by 14-15 d, and can be 
reliably detected on the surface of oligodendrocytes only af- 
ter 20 d. 
Some cell death was apparent over time in cultured oligo- 
Peptide IV 
I  [G  L  LEC  CAR]C  LVGAP  FAS  LVATGL  C  FF  GVALF  C  GC  G  HEALT  40 
Peptide II 
41  G  TiE  K  L  I  E  T  Y  F  S  KN  Y  Q  D  Y  EIY  L  I  NV  I  HAF  Q  YBV  I  g  G  T  AS  F  F  F  L  80 
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Peptide 1 
Y  G  ALL  LAE  G  F  Y  T  T  G  AVRQ  I  F  G  D  Y  KT  T  I  CIG  KG  L  S  ATVT  G  G  Q  81  120 
121  KGRGS  RIGQHQAHS  LERVCTC  LGKWLGHPD  KFVG  I  TYALTV  160 
:::::~:~:~:h::::.::<:::  <::::::: f ;::::::::~:~=  ::: :::::::::::::::::::::::::::::::;  ::::::::::::::::::::::::::::::  :::: 
•  Peptide  VI  .  Peptide  111 
161  v  W  L  LcV  F  A  CiS  A  V  P  V  Y  I  Y  F  N  T  W  T  TIC  Q  S  I  A  F  P  SIK T  S  A  S  I  G  S  L  C  200 
201  A  D  A  RIM  Y  G  V  L  P  W  N  A  F  P  G  K  V  C  G  S  N  L  L  S  I  C  K  T  A  E  F  Q  M  T  F  H  L  F  I  240 
Peptide V 
241  AAFVGAAATLVS  L  L  T  F  M  I  AAT  YN  F  AVL[KLMGRGTKFI  276 
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Figure 2. Location of the synthetic peptides in the PLP protein. The amino acid sequence of murine PLP (21) is shown. Peptide sequences 
are boxed; hydrophobic stretches A-D are underlined.  The bovine sequence at position 198 has a threonine instead of serine (27, 38); PLP 
III was synthesized with a threonine at 198 since the human or rodent sequence was not available at the time these studies were initiated. 
The Journal of Cell Biology, Volume 109,  1989  720 Figure 3. Immunofluorescent staining of cultured oligodendrocytes with various anti-PLP peptide antibodies. With PLP I antibody (a and 
b), the patterns of staining on living (a) and fixed (b) cells are compared. After staining of living cells, numerous small dots are seen on 
the surface of  the cell body (very bright fluorescence) and processes (a, arrow). When staining is performed after fixation and permeabiliza- 
tion, PLP is seen in small dots and larger clusters along the processes as well as in the cytoplasm of the perinuclear region. In c-e, staining 
of living oligodendrocytes with three other anti-peptide  antibodies (V, 111, and 111, respectively) is shown. Bar, 10 #m. 
dendrocytes, raising the possibility that membrane fragments 
containing PLP could interact with the surface of  living cells. 
This, however, would create a variable and irregular pattern 
of surface staining which was not observed. In fact, surface 
staining always revealed a regular dotted pattern over the cell 
body and processes. A curious phenomena observed in some 
cultures enriched in astrocytes was the presence of PLP im- 
munoreactivity in glial fibrillary acidic protein-positive cells 
(not illustrated). Although the astrocytic staining could result 
from phagocytosis of cellular debris, our recent discovery 
that nonmyelinating Schwann cells synthesize PLP (44) raises 
the intriguing possibility that the PLP gene may be activated 
in astrocytes upon culturing. 
Protease Cleavage of ExtraceUular PLP Domains 
To confirm the presence of PLP domains on the extracellular 
face of the plasma membrane, cultures were treated with pro- 
tease  and  subsequently  dual  labeled  with  anti-GC  and 
anti-PLP antibodies. For these experiments, cells had to be 
stained in suspension because the enzyme treatment detached 
oligodendrocytes from their substrate. Potential trypsin cleav- 
age sites within the PLP molecule are depicted in Fig. 6. As 
shown  in Table I,  trypsin treatment resulted in  a  marked 
reduction  in  the  number  of living  oligodendrocytes with 
surface-labeled PLP I, III, and IV domains. The hydropho- 
bic domain VI was variably affected but never eliminated by 
trypsin despite being flanked by potential trypsin cleavage 
sites (Fig. 6). The persistence of the PLP VI epitope on the 
oligodendrocyte surface after trypsin treatment could be due 
to an association of this hydrophobic domain with the oligo- 
dendrocyte membrane.  Therefore, we treated the cultures 
with chymotrypsin, which could cleave within the PLP VI 
domain at any of its numerous aromatic residues, and ob- 
tained a 78 % reduction of staining of living oligodendrocytes 
(Table I). 
Hudson et al. Assembly of PLP into the Oligodendrocyte Membrane  721 Figure  4.  Specific  peptide  competition of PLP antibody binding.  Living cultures  were stained  simultaneously  with anti-PLP IV and 
anti-GC, in the presence of peptide  IV (a-c) or peptide  I (d-e). Shown are phase (a and d), GC (b and e), and PLP IV (c and f) im- 
munofluorescence  of one cell from each condition. GC staining is not affected by the presence of either peptide.  PLP IV immunostaining 
is abolished  by the specific  peptide  (c) but is undiminished  in the presence of the unrelated  peptide  (f).  Bar,  20 #m. 
The carboxy terminus of PLP (domain V) was unusually 
resistant to trypsin cleavage despite the presence of three ar- 
ginine and lysine residues in this 9-amino acid domain. The 
immunofluorescent  staining  of this  domain  was  even  en- 
hanced after trypsin treatment;  all  GC-positive cells could 
be stained with anti-PLP V  antibody, and the fluorescence 
was  much  more  intense  than  observed  for nontrypsinized 
cells. This suggests that the carboxy terminus of PLP is inac- 
Figure 5. Distribution  of cytoplasmic PLP II immunoreactivity.  This oligodendrocyte  was stained for GC, fixed, permeabilized,  and stained 
with  PLP II antibody.  PLP II immunoreactivity (a) exhibits  a diffuse cytoplasmic distribution.  Marked GC immunostaining  (b) in dots 
and  patches  clearly identifies  this  cell  as an oligodendrocyte.  Bar,  10 #m. 
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Figure 6.  Mapping of the po- 
tential  trypsin sites along the 
different extracellular PLP do- 
mains. 
cessible to trypsin cleavage due to interactions with other ex- 
tracellular domains and these interactions are partially dis- 
rupted by trypsin treatment. The addition of low levels of 
detergent slightly facilitated trypsin cleavage of the amino 
acid stretch encompassing PLP V. PLP V staining was mark- 
edly reduced (by 45%) with chymotrypsin treatment. 
Importantly, neither the trypsin or chymotrypsin treatment 
breached the cytoplasmic membrane or exposed any cyto- 
plasmic proteins, as evidenced by the lack of staining of actin 
or the cytoplasmic protein MBP in parallel experiments. 
Complement-dependent Lysis of Oligodendrocytes 
Mediated by Antibody to Extracellular PLP Domains 
To further verify that the carboxy terminus of PLP resides 
on the extracellular face, despite its partial resistance to pro- 
tease cleavage, cells were incubated with this anti-peptide V 
antibody in the presence of complement and examined for ly- 
sis.  PLP V was compared with two other trypsin-sensitive 
extracellular domains, PLP I and PLP III. Table II shows that 
anti-PLP I, III, and V antibodies can each induce comple- 
ment-mediated lysis of oligodendrocytes at the appropriate 
dilution of antibody. These results indicate that the PLP V 
epitope as well as PLP I and III are present on the extracellu- 
lar surface of the oligodendrocyte plasma membrane and can 
mediate complement-dependent lysis of oligodendrocytes. 
When cells were pretreated with trypsin, the ability of anti- 
PLP I and III antibodies to lyse cells in a complement-depen- 
Table L Cleavage of  Extracellular PLP Domains 
with Protease 
Reduction of oligodendrocytes 
Antibody  Protease  expressing surface PLP* 
% 
PLP I  Trypsin  67  +  12 
Chymotrypsin  40 
PLP III  Trypsin  100 
PLP IV  Trypsin  80  +  28 
PLP V  Trypsin  0  +  0 
Trypsin*  9 
Chymotrypsin  45 
PLP VI  Trypsin  18  +  31 
Trypsin*  23 
Chymotrypsin  78 
* For each experiment, ,x, 100 untreated and 100 protease-treated cells from a 
20-37-d (rat age) culture were scored for GC and PLP. Results are expressed 
as the reduction in the percentage of cells stained for GC that also stain for PLP 
after protease treatment. Multiple experiments were carried out with trypsin- 
treated cultures of different ages and the results expressed as the mean +  SD. 
:i: 0.01% Triton X-100 included in trypsin incubation. 
dent fashion was markedly reduced, indicating that the pro- 
tease was effective in removing much of these PLP epitopes 
from the extracellular surface. Trypsin cleavage had little 
effect on the amount of lysis detected in cells treated with 
PLP V antibody plus complement; this suggests that the PLP 
V domain remained on the surface after trypsin treatment, 
in agreement with the surface labeling of this epitope on 
trypsinized oligodendrocytes described above. 
Distribution of  PLP Compared with Other 
Myelin Constituents 
When living oligodendrocytes were labeled with mixtures of 
anti-GC and anti-peptide antibodies, the GC immunofluo- 
rescence exhibited a patched surface pattern like that of the 
PLP  immunofluorescence, and the  GC  and  PLP patches 
were often coincident (Fig. 4, e and f).  However,  GC im- 
munofluorescence did not show patching when staining was 
performed on intact fixed cells. When cells were stained live 
with anti-PLP peptide antiserum, fixed, and then stained for 
GC, we saw patches of PLP immunofluorescence distributed 
along processes and cell bodies that were uniformly stained 
for GC (Fig.  7, a  and b).  It thus appears that patched GC 
Table II. Complement-dependent Lysis of Oligodendrocytes 
with Anti-peptide Antibodies 
Amount of lysis detected 
by trypan blue staining* 
Anti-peptide antibody  Antibody dilution*  -Trypsin  +Trypsin 
%  % 
PLP V  1:2  92  90 
1 : 10  54  65 
1:50  46  55 
1:100  31  40 
PLP I  1:2  69  20 
1:30  69  7 
i:100  38  0 
PLP III  1:30  94  20 
1:100  0  0 
* Undiluted antibody was  l  mg/ml. 
* Lysis is expressed as 
(%  of cells treated  with anti-PLP 
antibody  +  complement that are 
trypan blue positive) 
(% of cells treated with 
complement that are trypan 
blue positive) 
(%  of cells treated with anti-GC 
antibody  +  complement that are 
trypan blue positive) 
(% of cells treated with 
complement that are trypan 
blue positive) 
Hudson et al. Assembly of PLP into the Oligodendrocyte Membrane  723 Figure 7.  Distribution of surface PLP (a) compared with GC (b) and of cytoplasmic PLP (c) compared with cytoplasmic MAG (d).  In 
a  and b, staining  was carried out by procedure 2 of Materials and Methods.  PLP IV immunoreactivity is seen in clusters on the living 
cell membrane (a), while GC shows a uniform distribution (b). Inside the processes of fixed and permeabilized oligodendrocytes, PLP I 
(c) and MAG (d) appear localized in different dots and patches and the PLP clusters are larger.  Bar,  10 tim. 
immunofluorescence,  seen only with  GC  staining  of living 
cells,  reflects the aggregation of bound  antibody  molecules 
before fixation and not the native distribution of the GC anti- 
gen, as also noted by Dyer and Benjamins (18,  19). PLP was 
always distributed in clusters in our surface-stained prepara- 
tions;  however, these preparations  involved exposure of liv- 
ing  cells  to  PLP  antibodies.  The clustered  pattern  of PLP 
surface staining  illustrated  here may also result from aggre- 
gation  secondary  to antibody  binding,  and  our data do not 
exclude a uniform distribution of PLP in the unperturbed na- 
tive membrane. 
We  previously  found  MBP  and  cytoplasmic  PLP  to  be 
colocalized  in  clusters  within  oligodendrocyte  processes 
(16).  Furthermore,  cytoplasmic  staining  for  both  antigens 
preceded the appearance  of PLP on the external  surface of 
the oligodendrocyte plasma membrane.  In the present study 
we have found that MAG staining  was not colocalized with 
cytoplasmic PLP (Fig.  7,  c  and d).  Within oligodendrocyte 
processes double stained by two-color immunofluorescence, 
MAG was visualized as numerous small dots, possibly trans- 
port  vesicles,  that  rarely  coincided  with  dots  and  larger 
clusters stained by PLP I antibody (Fig. 7, c and d). In addi- 
tion, PLP also formed larger cytoplasmic clusters at the very 
extremities of the processes, where MAG was not seen (Fig. 
7,  c  and d).  This  segregation  suggests that  MAG and  PLP 
are transported to the oligodendrocyte membrane in different 
populations  of vesicles. 
Discussion 
In the present study,  we have probed cultured oligodendro- 
cytes with  antibodies  to  various domains  of PLP  and  have 
i 
vl  E.^.  l  V.,=COOH 
Extracellular  1 IV  /"-'/  1~  J~L~IIII~"(~"'  za'~z~ 
........  ..................  ........ 
Cytoplasmic 
Face  ii 
Figure 8.  Orientation of PLP in the oligodendro- 
cyte plasma membrane. A linear representation of 
the PLP molecule is drawn to scale, with the loca- 
tion of the synthetic peptides (I-VI) depicted by the 
thick lines and the four hydrophobic regions (A-D) 
shown  as  tx-helices.  Both  the  amino  (NH2) and 
carboxy (COOH) termini  are  shown on  the  ex- 
tracellular face of the lipid bilayer (dashed line). 
The amino acid residues marking the borders of 
the hydrophobic regions are numbered (see Fig. 2 
for the precise location of the synthetic peptides 
and the hydrophobic regions). The region deleted 
in  DM20  (amino acids  116-150)  is bounded  by 
arrows. 
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living oligodendrocytes. These observations allow us to pro- 
pose the model for the orientation of PLP in the oligodendro- 
cyte plasma  membrane presented  in  Fig.  8.  Most  of the 
hydrophilic portions of the protein, including the amino and 
carboxy termini, were detected on the extracellular surface 
of the plasma membrane and were accessible to exogenous 
protease. The only negatively charged domain resided on the 
cytoplasmic face. Contrary to computer predictions (Fig.  1; 
reference 27), of the four hydrophobic segments large enough 
to cross the membrane, only two (A and B) are likely to be 
membrane-spanning domains. Domain C does not appear to 
loop in and out of the membrane as proposed by Stoffei et 
al. (62), since it was immunostained by anti-peptide VI anti- 
body and cleaved by chymotrypsin. The extramembrane lo- 
cation of domain C is supported by the observation of Kahan 
and Moscarello that a photoactivated hydrophobic reagent la- 
beled the transmembrane helices A and B but did not interact 
with domain C (24). The disposition of the hydrophobic do- 
main D  is not precisely known since an anti-peptide anti- 
body was not prepared to this segment, but it probably resem- 
bles and possibly interacts with the similarly hydrophobic, 
highly c~-helical domain C. If domain D was buried within 
the lipid bilayer, the extracellular location of the carboxy ter- 
minus dictates that domain D would enter and exit the bilayer 
on  the  same  face of the  membrane.  The  unreliability of 
computer-generated predictions for the transmembrane orien- 
tation of PLP has been likewise observed for other mem- 
brane proteins, notably the acetylcholine receptor (9, 71) and 
the 32-kD chloroplast thylakoid membrane protein, which 
Sayre et al.  found to contain five instead of the predicted 
seven transmembrane  helices  (58).  Among proteins  with 
multiple transmembrane helices (for review see Wickner and 
Lodish [67]),  PLP may not be unique in orienting both its 
amino and carboxy termini on the extracellular face of the 
plasma membrane, as Schofield et al. speculate that the 3,-ami- 
nobutyric acid receptor may also position both termini ex- 
tracellularly (59). 
It is of note that the structure of PLP we propose, with the 
majority of the molecule on the extracellular face and only 
a small cytoplasmic domain, resembles the predicted struc- 
ture of the peripheral nervous system counterpart of PLP, the 
P,,  glycoprotein  (29).  Our  results  also  predict  that  the 
DM20 protein, which is produced by alternative splicing at 
the PLP locus (21, 40) and is deleted for the small stretch 
encompassing epitope I  (66)  (Fig.  8),  should display the 
structural features of PLP and function in a similar manner. 
Finally, our model indicates that if PLP and MBP do specif- 
ically interact, as has been suggested by cross-linking and 
binding studies (for review see Braun [6]),  this interaction 
must involve domain II (Fig. 8), the only PLP domain pres- 
ent on the cytoplasmic surface where MBP is located. 
The topology of PLP in the plasma membrane (Fig.  8) 
resembles the orientation of PLP in compact myelin pro- 
posed by Stoffel et al. (62) only in the amino-terminal half 
of the protein. In both the plasma membrane and in myelin, 
the hydrophilic domains of PLP stained by anti-peptide anti- 
bodies I, III, and IV reside on the extracellular face, which 
forms  the  intraperiod  line  in  compact  myelin,  and  the 
hydrophilic domain II resides on the cytoplasmic face. The 
two models differ, however,  in the disposition of the hydro- 
phobic domains C and D and the carboxy terminus. These 
differences are explicable in view of the methods used to ana- 
lyze  PLP  structure  in  compact  myelin.  Hyposmotically 
shocked compact myelin, which was presumably dissociated 
at the intraperiod line, was trypsin treated and the largest 
three tryptic fragments were partially sequenced (62).  Since 
the  hydrophobic domains C  and  D  lack trypsin cleavage 
sites, trypsin fragments analyzed would be identical whether 
C and D were in or out of the bilayer. Moreover, the carboxy 
terminus was intractable to trypsin digestion (see Results) 
under conditions similar to those used by Stoffel et al. (62) 
despite the presence of arginine and lysine in this domain. 
As the hyposmotic shock method assigned domains that were 
not cleaved by trypsin to the major dense line, the carboxy 
terminus in the Stoffel model was shown on the cytoplasmic 
face. The inaccessibility of PLP's carboxy terminus in com- 
pact myelin, which would complicate analyses dependent on 
protease treatment, was also demonstrated by Nussbaum et 
al. (43). The disparity between the two models of PLP topol- 
ogy could also be reconciled if PLP rearranges during its 
transition from plasma membrane to compact myelin. While 
conformational changes due to aggregation, acylation, or 
disulfide bridge formation are anticipated during myelin as- 
sembly, it is unlikely that these events could radically alter 
the orientation of PLP in the membrane. Nevertheless, the 
PLP topology we propose here should be further explored 
in myelinating oligodendrocytes. 
Our model is supported by the electron density profiles of 
the  cytoplasmic and  extracellular spaces  calculated from 
measurements of central nervous system myelin by Inouye 
and Kirschner (23).  The location of the majority of the PLP 
molecule on the extracellular face of the membrane (Fig. 8) 
is consistent with the observed electron density profile of the 
intraperiod line, which is much higher than either the Stoffel 
et al. (62) or Laursen et al. (27) models would predict (23). 
During compaction of the myelin sheath, the apposed ex- 
tracellular faces of adjacent lipid bilayers fuse to form the in- 
traperiod line. The presence of  the majority of  the PLP mole- 
cule (residues 1-8, 88-276; Fig. 8) in the intraperiod region 
indicates that this abundant protein may function to maintain 
the correct spacing between bilayers. A  structural role for 
PLP as a strut that preserves the intraperiod structure was 
originally proposed by Kirschner et al. (25) and is substan- 
tiated by recent work on the jimpy mouse mutant. In jimpy 
mice, aberrant splicing of PLP mRNA results in the absence 
of normal PLP protein (12, 21, 22, 31, 37, 39, 41, 54).  The 
myelin sheaths formed by jimpy oligodendrocytes have a 
much condensed intraperiod line (17) consistent with a role 
for PLP as a strut.  Homophilic interactions of PLP mole- 
cules could contribute significantly to the intraperiod struc- 
ture of the myelin sheath. Two posttranslational events may 
be critical in mediating these homophilic interactions: PLP 
molecules in apposing bilayers and/or within a bilayer could 
be cross-linked by disulfide bridges between loops IV, I, and 
III as previously characterized (27, 61, 62) or PLP molecules 
could aggregate via the hydrophobic, or-helical domains C 
and D.  Another posttranslational modification, the attach- 
ment of palmitic acid to domain III shortly before or during 
the insertion of PLP into myelin, could also act to maintain 
spacing, especially if the covalently bound fatty acid interca- 
lates into the apposing lipid bilayer as proposed by Laursen 
et al. (27).  The other two models of PLP topology (27, 62) 
are also consistent with homophilic interactions of PLP mol- 
ecules within and between bilayers. 
PLP is synthesized in the RER and can be detected in vivo 
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gous  to other membrane-spanning  proteins  (55,  67),  PLP 
must have at least one internal  signal sequence (uncleaved) 
that directs its  insertion into the RER membrane and one 
stop-transfer sequence (within domain A). One of the rate- 
limiting steps in the transport  of proteins from the RER is 
their correct folding or the assembly of protein monomers 
with their cognate partners  (e.g., heavy and light chains of 
IgM)  or with themselves  (e.g.,  trimers of influenza virus 
hemagglutinin),  as reviewed by Pfeffer and Rothman  (47). 
The capacity of PLP to aggregate  in vitro even in the pres- 
ence of strong denaturants  (6, 28) suggests that PLP mono- 
mers may assemble before exiting the ER in transport vesi- 
cles for the Golgi region. 
Protein  sorting  occurs chiefly  in the  Golgi  stacks  (47), 
where PLP may be directed by either bulk flow to the plasma 
membrane in vesicles that are  nonselective with regard  to 
their contents or be packaged in a signal-dependent fashion 
into  vesicles  whose transport  to the  myelin  membrane  is 
regulated.  Our finding of prolonged delay between the ac- 
cumulation of PLP in the cytoplasm of cultured oligodendro- 
cytes and the appearance of PLP on the surface of the plasma 
membrane  (see  Results;  reference  16)  suggests  that  PLP 
transport follows a regulated  pathway. Since MAG and PLP 
do not colocalize within the cytoplasm,  it appears  that the 
transport of PLP occurs via vesicles different from those that 
transport  MAG, a conclusion anticipated  by their disparate 
kinetics of transport (16) and by their ultimate location in dis- 
tinct compartments of the myelin sheath (32, 65). Cytoplas- 
mic movement of these two populations of vesicles seems in- 
dependently regulated, since MAG moves from perikarya to 
processes of cultured oligodendrocytes days earlier than PLP 
does (16). 
The transport of PLP to the cell processes appears to occur 
independently  of the  other  myelin  constituents  that  were 
monitored by immunostaining: GC, MBP, and MAG.  GC is 
established  throughout  the  extracellular  surface  of  the 
oligodendrocyte processes days before PLP synthesis initi- 
ates (16).  MBP is sometimes colocalized with internal PLP 
clusters and dots as shown earlier (16); this initial association 
of MBP and PLP may be mediated by the single cytoplasmic 
domain of PLP (Fig. 8). As discussed above, MAG and PLP 
appear to be transported by distinct, independently regulated 
vesicular transport systems. This segregation of MAG from 
PLP is consistent with the proposed role for MAG, which is 
structurally  similar to cell adhesion molecules (2, 26, 56), 
in  mediating  contacts  between  oligodendrocyte  processes 
and axons before being excluded from compact myelin (32, 
65). Thus, an initial event in myelin assembly could be the 
sorting of myelin constituents based on their ultimate  desti- 
nation in the myelin sheath.  Such events may be enhanced 
when oligodendrocytes are presented with their target neu- 
rons and, therefore, constitute the initial events in myelin as- 
sembly. The complete elucidation of these events will require 
coculture with neurons in a myelinating system (69) as well 
as  ultrastructural  analysis  of immunolabeled  myelinating 
cells. 
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